Physician profile
John Scopetta
NPI 1417181819
$14,560.55
in general payments reported to CMS, 2019-2025
30 companies · $5,410 in 2025
The $5,410 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,097 · 2022: $1,626 · 2023: $2,506 · 2024: $3,923 · 2025: $5,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $341 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,278.24 |
| Education | $341.29 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $218.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,737.48 | 2021-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $1,302.73 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,222.74 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $1,208.31 | 2023-2025 | Zoryve |
| Genzyme Corporation | $1,197.54 | 2021-2025 | |
| Ucb, INC. | $906.64 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $765.76 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $705.43 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $623.82 | 2023-2025 | Nemluvio, Aklief |
| Janssen Scientific Affairs, LLC | $482.09 | 2024-2025 | Tremfya |
| Incyte Corporation | $345.09 | 2021-2025 | Opzelura |
| Amgen INC. | $325.73 | 2022-2025 | Otezla |
| Dermavant Sciences, INC. | $319.01 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $279.67 | 2022-2025 | Odomzo, Blu-U |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $242.13 | 2024-2025 | Siliq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $189.84 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $161.95 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.08 | 2022-2023 | Spevigo, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $105.06 | 2025 | Sotyktu |
| Organon LLC | $83.23 | 2025 | Vtama |
| Sandoz INC. | $34.89 | 2024 | Hyrimoz |
| Left Coast Surgical INC | $31.93 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $28.00 | 2022 | |
| Biofrontera INC. | $25.33 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Blueprint Medicines Corporation | $21.09 | 2022 | |
| Kyowa Kirin, INC. | $19.00 | 2024 | Poteligeo |
| Genentech USA, INC. | $16.19 | 2021 | |
| Leo Pharma INC. | $15.25 | 2024 | Adbry |
| Strata Skin Sciences, INC. | $14.12 | 2022 | |
| Celltrion USA INC. | $13.42 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Scopetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.